Merck: adjusted net income up fivefold in 2024

(CercleFinance.com) - Merck reports sales of $64.
16bn for 2024, up 7% on 2023 (or +10% at constant exchange rates), notably driven by Keytruda sales, up 18% to $29.5bn. However, NB: pmt -9%.

Management also highlights the successful launch of WINREVAIR and the solid performance of the Animal Health business.

FY adjusted net income came to $19.44bn, i.e. a 5-fold increase on the previous year ($3.83bn), giving adjusted EPS of $7.65 versus $1.51.

In Q4, sales were $15.6bn, up 7% (+9% at constant exchange rates), with net income of $4.37bn (vs. $66m a year earlier) and adjusted EPS of $1.72 (vs. $0.03 a year earlier).

For 2025, Merck is targeting worldwide sales of $64.1bn to $65.6bn and adjusted EPS of $8.88 to $9.03.


Copyright (c) 2025 CercleFinance.com. All rights reserved.